At a glance
ClinicalIndex Comparison RecordPhase 2Active· 113 enrolled
Drug / intervention
acalabrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating acalabrutinib, rituximab (IV), and 1 other intervention for Non Hodgkin Lymphoma. Active but no longer recruiting, targeting 113 participants across 32 sites in 3 countries.
Detailed Summary
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Hodgkin Lymphoma
CountriesCanada, Italy, United States
CollaboratorsAstraZeneca
Timeline
Phase 2Active
201520162017201820192020202120222023202420252026202720282029
First PostedJul 2014
Enrollment StartDec 2014
Primary CompletionAug 2023
TodayJul 2026
Study CompletionDec 2028
First PostedJul 3, 2014
Enrollment StartDec 29, 2014
Primary CompletionAug 25, 2023
Study CompletionDec 29, 2028
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 12.0 years ago
Interventions
acalabrutinibdrug
rituximab (IV)drug
Lenalidomidedrug